Developing eye-tracking tools for early Alzheimer's risk assessment
Alzheimer's disease develops long before memory loss becomes apparent. Early assessment often requires specialist services, making it difficult to identify people for prevention research before symptoms emerge. Uneven access to testing also limits participation in studies across different populations.
Herencia is developing non-invasive tools to assess Alzheimer's risk through pupil responses and decision behaviour. Its approach aims to make early assessment accessible in lean clinical settings and support recruitment into prevention research.
What stands out about Herencia
The University of Antioquia provided a 130,000 m² site for Herencia’s planned Villa Aliria Alzheimer’s research and care village.
Herencia is an ETH Zurich spin-off developing pupil-based digital biomarkers for early Alzheimer’s risk assessment.
Herencia’s founders are testing and refining their early-detection method with the University of Antioquia’s genetic Alzheimer’s cohort in Colombia.
ETH Zurich's international patent application WO2026062089A1 for pupil-based Alzheimer's risk assessment was published in March 2026.
Get a curated pipeline of healthcare and life sciences startups aligned with your investment thesis.